Hims & Hers is a direct-to-consumer telehealth and pharmacy platform that connects patients with licensed providers and delivers prescription treatments, primarily through recurring subscriptions. Customers complete an intake questionnaire online, consult with a provider, and receive compounded medications shipped directly to their door. The platform covers sexual health, hair loss, dermatology, mental health, weight loss (including GLP-1 injectables), and hormone health, organized under two consumer brands: Hims for men and Hers for women. Weight loss is currently the fastest-growing specialty and the most important revenue driver. Hims & Hers owns its own compounding pharmacies, a 503B outsourcing facility, a peptide manufacturing facility, and a lab testing facility — giving it control over formulation, quality, and cost. The company does not accept insurance; customers pay entirely out of pocket, and Hims & Hers competes heavily on price and convenience. Revenue is driven by subscriber count and average revenue per subscriber, with higher-ARPU weight loss subscribers increasingly shifting the mix. The company ended Q3 FY25 with approximately 2.4M subscribers. Growth priorities include new specialties (testosterone, menopause, longevity), deeper personalization using lab and subscriber data, AI-powered provider and patient tools, pharmaceutical partnerships, and international expansion through acquisitions including Zava in Europe and the pending Eucalyptus deal covering Australia, the U.K., Germany, Canada, and Japan.